“We see opportunities across Asia with India as one of the key markets”

Headquartered in Sweden, Bio-Works Technologies AB carries out R&D, manufacturing and supply of agarose-based resins used to separate proteins and other biomolecules.

- Jonathan Royce

In this large and well-established area, the company’s products stand out as innovative and cutting edge with exceptional performance. They are used in academic research laboratories, biopharmaceutical companies, and many more areas. Amidst the pandemic, the company announced the appointment of Jonathan Royce as the new Chief Executive Officer (CEO). Royce has a background in senior leadership roles within large-scale suppliers to the biopharmaceutical market including MerckMillipore and GE Healthcare Life Sciences (now Cytiva). BioSpectrum interacted with Jonathan Royce to find out what Bio-Works has in store for the Indian market. Edited excerpts;

What were the highlights at Bio-Works in 2020?

2020 was a year in which Bio-Works expanded its global reach in several key markets. We established a US-subsidiary and hired two sales managers in the US market (one in Boston, one in San Diego) and substantially grew our business in key Asian markets, most notably South Korea. We brought on Dr. Ravi Rayanade in India as a Director Regional Sales to better be able to serve our growing base of customers in the Indian biotech market. And we added new distributors in India (Arihant and BioLinx) and Taiwan (Yong Chien Technology). Also during the past year, Bio-Works continued its quality improvements with a successful re-certification against the ISO 9001:2015 quality standard. This certification ensures that Bio-Works resins meet the strict requirements of users, who are producing biopharmaceuticals under Good Manufacturing Practices (GMP). We also concluded a number of studies designed to strengthen the data offered to users in our Regulatory Support Files.

What are the major plans for 2021?